Accumulation of VEGFR2 in zoledronic acid-treated endothelial cells

Molecular Medicine Reports

Volumn 3, Issue 3, 2010, Pages 399-403

  Basi, David L ^a   Lee, Soo Woon ^c   Helfman, Sarah ^a   Mariash, Ami ^a   Lunos, Scott A ^b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c Inje University College of Medicine   (South Korea)

Author keywords

Bisphosphonates; Endothelial cells; Pathogenesis; Vascular endothelial cell growth factor receptor 2

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; GERANYLGERANYL PYROPHOSPHATE; MESSENGER RNA; MEVALONIC ACID; VASCULOTROPIN RECEPTOR 2; ZOLEDRONIC ACID;

ARTICLE; CELL MIGRATION; CELL SURFACE; CHEMOTAXIS; COMPARATIVE STUDY; CONFOCAL MICROSCOPY; CONTROLLED STUDY; ENDOTHELIUM CELL; FLOW CYTOMETRY; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RNA TRANSCRIPTION; UMBILICAL VEIN; WESTERN BLOTTING;

EID: 77952388048     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr_00000271     Document Type: Article

References (18)

1. Carteni G, Bordonaro R, Giotta F, Lorusso V, Scalone S, Vinaccia V, Rondena R and Amadori D: Efficacy and safety of zoledronic acid in patients with breast cancer metastatic to bone: a multicenter clinical trial. Oncologist 11: 841-848, 2006. (Pubitemid 44157572)
2. Lipton A, Small E, Saad F, Gleason D, Gordon D, Smith M, Rosen L, Kowalski MO, Reitsma D and Seaman J: The new bisphosphonate, Zometa (zoledronic acid), decreases skeletal complications in both osteolytic and osteoblastic lesions: a comparison to pamidronate. Cancer Invest 20 (Suppl 2): 45-54, 2002.
3. Wood J, Bonjean K, Ruetz S, Bellahcene A, Devy L, Foidart JM, Castronovo V and Green JR: Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther 302: 1055-1061, 2002. (Pubitemid 34920226)
4. Fournier P, Boissier S, Filleur S, Guglielmi J, Cabon F, Colombel M and Clezardin P: Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res 62: 6538-6544, 2002. (Pubitemid 35364119)
5. Giraudo E, Inoue M and Hanahan D: An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis. J Clin Invest 114: 623-633, 2004. (Pubitemid 39578752)
6. Cetinkaya BO, Keles GC, Ayas B and Gurgor P: Effects of risedronate on alveolar bone loss and angiogenesis: a stereologic study in rats. J Periodontol 79: 1950-1961, 2008.
7. Meyer RD, Singh A, Majnoun F, Latz C, Lashkari K and Rahimi N: Substitution of C-terminus of VEGFR-2 with VEGFR-1 promotes VEGFR-1 activation and endothelial cell proliferation. Oncogene 23: 5523-5531, 2004. (Pubitemid 39044063)
8. Hiratsuka S, Minowa O, Kuno J, Noda T and Shibuya M: Flt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice. Proc Natl Acad Sci USA 95: 9349-9354, 1998. (Pubitemid 28506234)
9. Rahimi N, Dayanir V and Lashkari K: Receptor chimeras indicate that the vascular endothelial growth factor receptor-1 (VEGFR-1) modulates mitogenic activity of VEGFR-2 in endothelial cells. J Biol Chem 275: 16986-16992, 2000.
10. Skobe M, Rockwell P, Goldstein N, Vosseler S and Fusenig NE: Halting angiogenesis suppresses carcinoma cell invasion. Nat Med 3: 1222-1227, 1997. (Pubitemid 27508822)
11. Lindner V and Collins T: Expression of NF-kappaB and I kappaB-alpha by aortic endothelium in an arterial injury model. Am J Pathol 148: 427-438, 1996.
12. Dougher M and Terman BI: Autophosphorylation of KDR in the kinase domain is required for maximal VEGF-stimulated kinase activity and receptor internalization. Oncogene 18: 1619-1627, 1999. (Pubitemid 29108062)
13. Balla G, Vercellotti G, Eaton JW and Jacob HS: Heme uptake by endothelium synergizes polymorphonuclear granulocyte-mediated damage. Trans Assoc Am Physicians 103: 174-179, 1990.
14. Basi DL, Ross KF, Hodges JS and Herzberg MC: The modulation of tissue factor by endothelial cells during heat shock. J Biol Chem 278: 11065-11071, 2003. (Pubitemid 36792657)
15. + T cell repopulation of lymphoid tissues after treatment of HIV-1 infection. Proc Natl Acad Sci USA 95: 1154-1159, 1998.
16. Guenther A, Gordon S, Tiemann M, Burger R, Bakker F, Green JR, Baum W, Roelofs AJ, Rogers MJ and Gramatzki M: The bisphosphonate zoledronic acid has antimyeloma activity in vivo by inhibition of protein prenylation. Int J Cancer 126: 239-246, 2010.
17. Clezardin P, Fournier P, Boissier S and Peyruchaud O: In vitro and in vivo antitumor effects of bisphosphonates. Curr Med Chem 10: 173-180, 2003.
18. Ewan LC, Jopling HM, Jia H, Mittar S, Bagherzadeh A, Howell GJ, Walker JH, Zachary IC and Ponnambalam S: Intrinsic tyrosine kinase activity is required for vascular endothelial growth factor receptor 2 ubiquitination, sorting and degradation in endothelial cells. Traffic 7: 1270-1282, 2006.